請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19150
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林慧玲(Fe-Lin Lin Wu) | |
dc.contributor.author | Shu-Jung Chang | en |
dc.contributor.author | 張書榕 | zh_TW |
dc.date.accessioned | 2021-06-08T01:46:45Z | - |
dc.date.copyright | 2016-08-26 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-09 | |
dc.identifier.citation | 1. Johnson HJS, K.S. Solid-organ transplantation. In: DiPiro JTT, R.L.; Yee, G.C., ed. Pharmacotherapy. 6 ed. New York: McGraw-Hill; 2005:1613-43.
2. Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantation. Expert opinion on pharmacotherapy 2008;9:635-43. 3. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996;62:920-6. 4. Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996;62:900-5. 5. Mourad M, Wallemacq P, De Meyer M, et al. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation 2008;85:S19-24. 6. Coto E, Tavira B. Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation 2009;88:S62-7. 7. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clinical pharmacokinetics 1995;29:404-30. 8. Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003;63:1247-97. 9. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. The New England journal of medicine 2007;357:2562-75. 10. Oberbauer R. Improved renal function in de novo renal transplant patients on sirolimus maintenance therapy following discontinuation of cyclosporine. Therapeutic drug monitoring 2005;27:7-9. 11. Kim IW, Noh H, Ji E, et al. Identification of factors affecting tacrolimus level and 5-year clinical outcome in kidney transplant patients. Basic & clinical pharmacology & toxicology 2012;111:217-23. 12. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. The New England journal of medicine 2002;346:580-90. 13. Borobia AM, Romero I, Jimenez C, et al. Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection. Therapeutic drug monitoring 2009;31:436-42. 14. O'Seaghdha CM, McQuillan R, Moran AM, et al. Higher tacrolimus trough levels on days 2-5 post-renal transplant are associated with reduced rates of acute rejection. Clinical transplantation 2009;23:462-8. 15. Han SS, Kim, D.H., Lee, S.M., Han, N.Y., Oh, J.M., Ha, J.W., Kim, Y.S. Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants. Kidney Res Clin Pract 2012;31:157-62. 16. Quteineh L, Verstuyft C, Furlan V, et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic & clinical pharmacology & toxicology 2008;103:546-52. 17. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clinical pharmacokinetics 2010;49:141-75. 18. Renders L, Frisman M, Ufer M, et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clinical pharmacology and therapeutics 2007;81:228-34. 19. MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2004;4:914-9. 20. Zhang X, Liu ZH, Zheng JM, et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clinical transplantation 2005;19:638-43. 21. Kim IW, Moon YJ, Ji E, et al. Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients. European journal of clinical pharmacology 2012;68:657-69. 22. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clinical pharmacokinetics 2004;43:623-53. 23. Floren LC, Bekersky I, Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clinical pharmacology and therapeutics 1997;62:41-9. 24. Zhao W, Elie V, Roussey G, et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clinical pharmacology and therapeutics 2009;86:609-18. 25. Antignac M, Barrou B, Farinotti R, Lechat P, Urien S. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. British journal of clinical pharmacology 2007;64:750-7. 26. Staatz CE, Willis C, Taylor PJ, Tett SE. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clinical pharmacology and therapeutics 2002;72:660-9. 27. Press RR, de Fijter JW, Guchelaar HJ. Individualizing calcineurin inhibitor therapy in renal transplantation--current limitations and perspectives. Current pharmaceutical design 2010;16:176-86. 28. Ware N, MacPhee IA. Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation. Current opinion in molecular therapeutics 2010;12:270-83. 29. Velickovic-Radovanovic R, Mikov M, Paunovic G, et al. Gender differences in pharmacokinetics of tacrolimus and their clinical significance in kidney transplant recipients. Gender medicine 2011;8:23-31. 30. Alldredge BK. Koda Kimble and Youngs Applied Therapeutics. 10 ed. United States: Lippincott Williams & Wilkins; 2012. 31. Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacology & therapeutics 2006;112:184-98. 32. Chen YH, Zheng KL, Chen LZ, et al. Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. Transplant Proc 2005;37:4246-50. 33. Dai Y, Hebert MF, Isoherranen N, et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006;34:836-47. 34. Morrissey PE, Gohh R, Shaffer D, et al. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. Transplantation 1997;63:845-8. 35. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2004;4:1289-95. 36. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997;64:436-43. 37. Herzer K, Strassburg CP, Braun F, et al. Selection and use of immunosuppressive therapies after liver transplantation: Current German practice. Clinical transplantation 2016. 38. Townsend CM. Sabiston Textbook of Surgery. 19 ed. United States: Saunders; 2012. 39. Goto T, Kino T, Hatanaka H, et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987;19:4-8. 40. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. The Journal of antibiotics 1987;40:1249-55. 41. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989;2:1000-4. 42. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet 1994;344:423-8. 43. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. The New England journal of medicine 1994;331:1110-5. 44. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997;63:977-83. 45. Klintmalm GB, Goldstein R, Gonwa T, et al. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. Transplant Proc 1993;25:679-88. 46. Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997;54:925-75. 47. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993;46:746-94. 48. Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000;59:323-89. 49. Rustin M. Tacrolimus ointment for the management of atopic dermatitis. Hospital medicine 2003;64:214-7. 50. Gewirtz AT, Sitaraman SV. Tacrolimus Fujisawa. Current opinion in investigational drugs 2002;3:1307-11. 51. Russell JJ. Topical tacrolimus: a new therapy for atopic dermatitis. American family physician 2002;66:1899-902. 52. Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. American journal of kidney diseases : the official journal of the National Kidney Foundation 2001;38:S25-35. 53. UNOS Market Share Report. Immunosuppression and practice trend. 2002. Chapter 4. Available online: http://wwwunos.org/. 54. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998;92:2303-14. 55. Jindal RM, Dubernard JM. Towards a specific immunosuppression for pancreas and islet grafts. Clinical transplantation 2000;14:242-5. 56. Stratta RJ. Immunosuppression in pancreas transplantation: progress, problems and perspective. Transplant immunology 1998;6:69-77. 57. Klein A. Tacrolimus rescue in liver transplant patients with refractory rejection or intolerance or malabsorption of cyclosporine. The US Multicenter FK506 Liver Study Group. Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 1999;5:502-8. 58. Laskow DA, Neylan JF, 3rd, Shapiro RS, Pirsch JD, Vergne-Marini PJ, Tomlanovich SJ. The role of tacrolimus in adult kidney transplantation: a review. Clinical transplantation 1998;12:489-503. 59. Dubinsky MC, Seidman EG. Novel immunosuppressive therapies for intestinal and hepatic diseases. Current opinion in pediatrics 1999;11:390-5. 60. Singer NG, McCune WJ. Update on immunosuppressive therapy. Current opinion in rheumatology 1998;10:169-73. 61. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clinical journal of the American Society of Nephrology : CJASN 2007;2:374-84. 62. de Jonge H, Naesens M, Kuypers DR. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Therapeutic drug monitoring 2009;31:416-35. 63. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clinical pharmacology and therapeutics 1995;57:281-90. 64. Regazzi MB, Rinaldi M, Molinaro M, et al. Clinical pharmacokinetics of tacrolimus in heart transplant recipients. Therapeutic drug monitoring 1999;21:2-7. 65. Backman L, Levy MF, Klintmalm G. Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group. Transplant Proc 1995;27:1124. 66. Winkler M, Ringe B, Jost U, Gubernatis G, Pichlmayr R. Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation. Transplant Proc 1993;25:2688-90. 67. Schwartz M, Holst B, Facklam D, Buell D. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. Transplant Proc 1995;27:1107. 68. Krensky AMV, F.; Bennett, W.M. Immunosuppressants, tolerogens, and immunostimulants. In: Brunton LLL, J.S.; Parker, K.L., ed. The pharmacological basis of therapeutics. 11 ed. New York: McGraw-Hill; 2006:1405-65. 69. Pons JA, Ramirez P, Revilla-Nuin B, et al. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clinical transplantation 2009;23:329-36. 70. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Therapeutic drug monitoring 2009;31:139-52. 71. Hansten PDH, J.R. Drug interactions analysis and management 2007. St. Louis, Missouri: Wolters Kluwer; 2007. 72. Venkataramanan R, Jain A, Warty VS, et al. Pharmacokinetics of FK 506 in transplant patients. Transplant Proc 1991;23:2736-40. 73. Nagase K, Iwasaki K, Nozaki K, Noda K. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. The Journal of pharmacy and pharmacology 1994;46:113-7. 74. Undre NA, van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999;31:296-8. 75. Mourad M, Wallemacq P, De Meyer M, et al. The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function. Clinical chemistry and laboratory medicine 2006;44:1192-8. 76. Kay JE, Sampare-Kwateng E, Geraghty F, Morgan GY. Uptake of FK 506 by lymphocytes and erythrocytes. Transplant Proc 1991;23:2760-2. 77. Kobayashi M, Tamura K, Katayama N, et al. FK 506 assay past and present--characteristics of FK 506 ELISA. Transplant Proc 1991;23:2725-9. 78. Piekoszewski W, Jusko WJ. Plasma protein binding of tacrolimus in humans. Journal of pharmaceutical sciences 1993;82:340-1. 79. Wallemacq PE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clinical pharmacokinetics 2001;40:283-95. 80. Hesselink DA, van Gelder T, van Schaik RH. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 2005;6:323-37. 81. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. The Journal of biological chemistry 1993;268:6077-80. 82. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995;23:1315-24. 83. Nakazawa Y, Chisuwa H, Ikegami T, et al. Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation. Transplantation 1998;66:1089-93. 84. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-61. 85. Vincent SH, Karanam BV, Painter SK, Chiu SH. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Archives of biochemistry and biophysics 1992;294:454-60. 86. Press RR, Ploeger BA, den Hartigh J, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Therapeutic drug monitoring 2009;31:187-97. 87. Bai JP, Lesko LJ, Burckart GJ. Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors. Pharmacotherapy 2010;30:195-209. 88. Rosso Felipe C, de Sandes TV, Sampaio EL, Park SI, Silva HT, Jr., Medina Pestana JO. Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs. Transplant Proc 2009;41:1441-55. 89. Capron A, Mourad M, De Meyer M, et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics 2010;11:703-14. 90. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clinical pharmacology and therapeutics 2007;82:711-25. 91. Li D, Gui R, Li J, Huang Z, Nie X. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. Transplant Proc 2006;38:2850-2. 92. Fredericks S, Moreton M, Reboux S, et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation 2006;82:705-8. 93. Barry A, Levine M. A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients. Therapeutic drug monitoring 2010;32:708-14. 94. Kamdem LK, Streit F, Zanger UM, et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clinical chemistry 2005;51:1374-81. 95. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug metabolism and pharmacokinetics 2007;22:328-35. 96. Wu MJ, Chang CH, Cheng CY, et al. Reduced variability of tacrolimus trough level in once-daily tacrolimus-based Taiwanese kidney transplant recipients with high-expressive genotype of cytochrome P450 3A5. Transplant Proc 2014;46:403-5. 97. Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. Journal of the American Society of Nephrology : JASN 2003;14:1889-96. 98. Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004;78:1182-7. 99. Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol 2001;41:289-97. 100. Kuypers DR, Claes K, Evenepoel P, et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clinical pharmacokinetics 2004;43:741-62. 101. Mourad M, Mourad G, Wallemacq P, et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 2005;80:977-84. 102. Marchesini G, Bua V, Brunori A, et al. Galactose elimination capacity and liver volume in aging man. Hepatology 1988;8:1079-83. 103. Woodhouse KW, Wynne HA. Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly. Clinical pharmacokinetics 1988;15:287-94. 104. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989;9:297-301. 105. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clinical pharmacology and therapeutics 1997;61:331-9. 106. Ginsberg G, Hattis D, Russ A, Sonawane B. Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals. Environmental health perspectives 2005;113:1243-9. 107. Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Molecular pharmacology 1992;41:1047-55. 108. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773-9. 109. Miura M, Satoh S, Kagaya H, et al. No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation. European journal of clinical pharmacology 2009;65:1047-53. 110. Jacobson PA, Schladt D, Oetting WS, et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2012;12:3326-36. 111. Gijsen V, Mital S, van Schaik RH, et al. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2011;30:1352-9. 112. Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002;24:330-50; discussion 29. 113. Schwartz JB. The influence of sex on pharmacokinetics. Clinical pharmacokinetics 2003;42:107-21. 114. Greenblatt DJ, von Moltke LL. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol 2008;48:1350-5. 115. Wolbold R, Klein K, Burk O, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003;38:978-88. 116. Christiaans M, van Duijnhoven E, Beysens T, Undre N, Schafer A, van Hooff J. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. Transplant Proc 1998;30:1271-3. 117. Sewing KF. Pharmacokinetics, dosing principles, and blood level monitoring of FK506. Transplant Proc 1994;26:3267-9. 118. Han N, Yun HY, Hong JY, et al. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. European journal of clinical pharmacology 2013;69:53-63. 119. Antignac M, Hulot JS, Boleslawski E, et al. Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. European journal of clinical pharmacology 2005;61:409-16. 120. Fukatsu S, Yano I, Igarashi T, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. European journal of clinical pharmacology 2001;57:479-84. 121. Jain AB, Venkataramanan R, Cadoff E, et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc 1990;22:57-9. 122. Winkler M, Ringe B, Rodeck B, et al. The use of plasma levels for FK 506 dosing in liver-grafted patients. Transplant international : official journal of the European Society for Organ Transplantation 1994;7:329-33. 123. Jain AB, Abu-Elmagd K, Abdallah H, et al. Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol 1993;33:606-11. 124. Lee JY, Hahn HJ, Son IJ, et al. Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients. Pharmacotherapy 2006;26:1069-77. 125. Hu RH, Lee PH, Tsai MK. Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients. Transplant Proc 2000;32:1689-92. 126. Jacobson P, Ng J, Ratanatharathorn V, Uberti J, Brundage RC. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone marrow transplantation 2001;28:753-8. 127. Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2003;9:130-7. 128. Katsakiori PF, Papapetrou EP, Sakellaropoulos GC, Goumenos DS, Nikiforidis GC, Flordellis CS. Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach. International journal of medical sciences 2010;7:94-100. 129. Hu RH, Lee PH, Chung YC, Huang MT, Lee CS. Hepatitis B and C in renal transplantation in Taiwan. Transplant Proc 1994;26:2059-61. 130. Kahan BD, Kramer WG, Wideman C, Flechner SM, Lorber MI, Van Buren CT. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 1986;41:459-64. 131. Manzanares C, Moreno M, Castellanos F, et al. Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients. Transplant Proc 1998;30:1264-5. 132. Horina JH, Wirnsberger GH, Kenner L, Holzer H, Krejs GJ. Increased susceptibility for CsA-induced hepatotoxicity in kidney graft recipients with chronic viral hepatitis C. Transplantation 1993;56:1091-4. 133. Baran DA, Galin I, Sandler D, et al. Tacrolimus in cardiac transplantation: efficacy and safety of a novel dosing protocol. Transplantation 2002;74:1136-41. 134. Warty V, Venkataramanan R, Zendehrouh P, et al. Distribution of FK 506 in plasma lipoproteins in transplant patients. Transplant Proc 1991;23:954-5. 135. Bauer LA. Applied clinical pharmacokinetics. 2 ed. New York: McGraw-Hill; 2008. 136. Undre NA, Schafer A. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Transplant Proc 1998;30:1261-3. 137. Zahir H, McLachlan AJ, Nelson A, McCaughan G, Gleeson M, Akhlaghi F. Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Therapeutic drug monitoring 2005;27:422-30. 138. Golubovic B, Vucicevic K, Radivojevic D, Kovacevic SV, Prostran M, Miljkovic B. Total plasma protein effect on tacrolimus elimination in kidney transplant patients--population pharmacokinetic approach. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2014;52:34-40. 139. Barraclough KA, Isbel NM, Johnson DW, Campbell SB, Staatz CE. Once- versus twice-daily tacrolimus: are the formulations truly equivalent? Drugs 2011;71:1561-77. 140. Hougardy JM, de Jonge H, Kuypers D, Abramowicz D. The once-daily formulation of tacrolimus: a step forward in kidney transplantation? Transplantation 2012;93:241-3. 141. Alloway R, Steinberg S, Khalil K, et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc 2005;37:867-70. 142. Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc 2005;37:1211-3. 143. Cross SA, Perry CM. Tacrolimus once-daily formulation: in the prophylaxis of transplant rejection in renal or liver allograft recipients. Drugs 2007;67:1931-43. 144. Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2009;9:2505-13. 145. de Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 2010;90:523-9. 146. Wu MJ, Cheng CY, Chen CH, et al. Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients. Transplantation 2011;92:648-52. 147. Hougardy JM, Broeders N, Kianda M, et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation 2011;91:566-9. 148. Crespo M, Mir M, Marin M, et al. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Transplant Proc 2009;41:2115-7. 149. Horowitz M, Fraser RJ. Gastroparesis: diagnosis and management. Scandinavian journal of gastroenterology Supplement 1995;213:7-16. 150. van Duijnhoven E, Christiaans M, Schafer A, Undre N, van Hooff J. Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. Transplant Proc 1998;30:1266-7. 151. Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 1997;29:1129-88. 152. Iber H, Sewer MB, Barclay TB, Mitchell SR, Li T, Morgan ET. Modulation of drug metabolism in infectious and inflammatory diseases. Drug Metab Rev 1999;31:29-41. 153. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clinical pharmacokinetics 2002;41:813-51. 154. Hronova K, Sima M, Svetlik S, Matouskova O, Slanar O. Pharmacogenetics and immunosuppressive drugs. Expert Rev Clin Pharmacol 2014;7:821-35. 155. Li JL, Wang XD, Chen SY, et al. Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. The pharmacogenomics journal 2011;11:300-6. 156. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature genetics 2001;27:383-91. 157. McCarthy AD, Kennedy JL, Middleton LT. Pharmacogenetics in drug development. Philosophical transactions of the Royal Society of London Series B, Biological sciences 2005;360:1579-88. 158. Walker DK. The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. British journal of clinical pharmacology 2004;58:601-8. 159. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clinical pharmacology and therapeutics 2003;74:245-54. 160. Wehland M, Bauer S, Brakemeier S, et al. Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenetics and genomics 2011;21:179-84. 161. Buendia JA, Bramuglia G, Staatz CE. Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of ta | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19150 | - |
dc.description.abstract | 簡介:
臨床觀察發現腎臟與肝臟移植的病人,即便使用相同劑量的tacrolimus (TAC),個體間的血中濃度變異還是很大。過去研究發現有許多因素可能會影響TAC的血中濃度,然而所獲得的結果缺乏一致性,故本研究將所有可能會影響TAC血中濃度的因素納入分析,探討各種因素對TAC血中濃度的影響。 方法: 本研究由兩部分組成:第一部分為因素分析,第二部分為基因多型性研究。納入條件包含在2008年1月1日至2015年7月31日腎臟或肝臟移植的病人,並且在移植後使用TAC作為免疫抑制劑且須持續服用至少6個月,此外移植時的年齡須介於20到 65歲。排除條件包含再移植或多重器官移植、非亞裔以及人類免疫缺乏病毒反應呈陽性的病人。TAC用劑量調整谷濃度(dose normalized trough concentrations,dnC0;與dosing weight and dose normalized trough concentrations,dnC0/DW)來表示,使用三個評估點:移植手術住院期間、移植後3個月以及移植後6個月。統計方法使用單變項及多元迴歸分析、獨立樣本t檢定、ANOVA(analysis of variance)、Chi-squared test以及Fisher's exact test。 結果: 本研究納入227個腎臟移植病人,在移植手術住院期間的多元迴歸分析,發現會顯著影響TAC dnC0或dnC0/DW的因素有年齡、性別以及有無使用proton pump inhibitors(PPI);在移植後3個月的多元迴歸分析,發現會顯著影響TAC dnC0或dnC0/DW的因素有年齡、性別、有無使用PPI、hemoglobin(Hb);在移植後6個月的多元迴歸分析,發現會顯著影響TAC dnC0或dnC0/DW的因素有年齡、性別、有無使用MMF(mycophenolate mofetil)或MPS(mycophenolate sodium)、hematocrit(Hct)以及類固醇的體重校正每日劑量。 本研究納入199個肝臟移植病人,在移植手術住院期間的多元迴歸分析,發現會顯著影響TAC dnC0或dnC0/DW的因素有TAC的劑型(Prograf ®或Advagraf ®)、有無使用類固醇、有無使用PPI以及albumin;在移植後3個月的多元迴歸分析,發現會顯著影響TAC dnC0或dnC0/DW的因素有Hb、AST(aspartate aminotransferase)、TAC的劑型(Prograf ®或Advagraf ®)、有無使用類固醇以及有無感染;在移植後6個月的多元迴歸分析,發現會顯著影響TAC dnC0或dnC0/DW的因素有AST、有無感染、Hb、TAC的劑型(Prograf ®或Advagraf ®)以及有無糖尿病。 基因多型性分析共納入55個腎臟移植病人,發現在移植後的三個評估點,一致顯示會顯著影響TAC dnC0與dnC0/DW的基因是CYP3A5*3,將病人分成CYP3A5表現型和CYP3A5非表現型,CYP3A5非表現型的TAC dnC0與dnC0/DW是CYP3A5表現型的1.8至2.7倍。 結論: 在腎臟移植的病人,會顯著影響TAC dnC0或dnC0/DW的因素有年齡、性別、有無使用PPI、Hb、Hct以及類固醇的體重校正每日劑量;在肝臟移植的病人,會顯著影響TAC dnC0或dnC0/DW的因素有TAC的劑型(Prograf ®或Advagraf ®)、有無使用類固醇、有無使用PPI、albumin、Hb、AST、有無感染以及有無糖尿病;在基因型的部分,CYP3A5基因變異在腎臟移植後的3個評估點皆會顯著影響TAC的dnC0與dnC0/DW。當上述因子有顯著改變時,需要密切監測病人的TAC血中濃度。 | zh_TW |
dc.description.provenance | Made available in DSpace on 2021-06-08T01:46:45Z (GMT). No. of bitstreams: 1 ntu-105-R03451005-1.pdf: 6355484 bytes, checksum: 50fefb8b7997a2232dcc863a1178ed3a (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 論文口試委員審定書 i
致謝 ii 縮寫表 iii 中文摘要 v Abstract vii 目錄 x 圖目錄 xiv 表目錄 xv 第一章、 前言 1 第二章、 文獻探討 3 2.1 腎臟移植的免疫抑制劑使用情形 3 2.2 肝臟移植的免疫抑制劑使用情形 3 2.3 Tacrolimus的介紹 4 2.3.1 Tacrolimus的作用機制 5 2.3.2 Tacrolimus的毒性 5 2.4 Tacrolimus的藥動學特性 6 2.4.1 吸收 6 2.4.2 分布 7 2.4.3 代謝及排除 7 2.5 臨床因素對tacrolimus藥動學的影響 8 2.5.1 年齡 9 2.5.2 性別 9 2.5.3 移植後天數(post-operative day,POD) 10 2.5.4 肝功能 10 2.5.5 HBV(hepatitis B virus)與HCV(hepatitis C virus) 11 2.5.6 腎功能 11 2.5.7白蛋白(albumin,Alb)與總蛋白(total protein,TP) 11 2.5.8血紅素(hemoglobin,Hb)與血比容(hematocrit,Hct) 12 2.5.9 Prograf ®與Advagraf ® 12 2.5.10 糖尿病(diabetes mellitus,DM) 12 2.5.11 感染 13 2.6 藥品對tacrolimus藥動學的影響 13 2.7 基因多型性對tacrolimus藥動學的影響 13 2.7.1 CYP3A5 14 2.7.2 CYP3A4 15 2.7.3 POR*28 16 2.7.4 ABCB1 16 第三章、研究目的及方法 18 3.1 研究目的 18 3.2 研究方法 18 3.2.1 研究架構 18 3.2.2 病人 19 3.2.3 臨床資訊收集之流程 19 3.2.4 TAC穩定狀態之C0 20 3.2.5 給藥體重(dosing weight,DW)定義 21 3.2.6 TAC劑量校正C0(dose normalized C0,dnC0)定義 21 3.2.7 TAC納入分析之時間點(data collection) 21 3.2.8 其它檢驗數據(laboratory data)之採檢日期 22 3.2.9 併用藥品(comedication)定義 23 3.2.10 TAC血中濃度檢驗方法 23 3.2.11 Genotyping方法 23 3.2.12 其它定義 24 3.2.13 統計分析 24 第四章、研究結果 28 4.1 腎臟移植 28 4.1.1 病人篩選流程 28 4.1.2 病人人口學資料 28 4.1.3 TAC劑量與血中濃度的變化 28 4.1.4 免疫抑制劑與併用藥品 29 4.1.5 生化檢驗值的變化 29 4.1.6 單變項及多變項分析 31 4.1.7 免疫抑制劑組合分析 34 4.1.8 基因多型性分析 35 4.2 肝臟移植 46 4.2.1病人篩選流程 46 4.2.2 病人人口學資料 46 4.2.3 TAC劑量與血中濃度的變化 46 4.2.4 免疫抑制劑與併用藥品 47 4.2.5 生化檢驗值的變化 48 4.2.6 單變項及多變項分析 49 4.2.7 免疫抑制劑組合分析 53 第五章、討論 57 5.1 腎臟移植 57 5.1.1 年齡 57 5.1.2 性別 58 5.1.3 MMF/MPS 59 5.1.4 基因多型性 60 5.2 肝臟移植 62 5.2.1 Prograf vs. Advagraf 62 5.2.2 Albumin 63 5.2.3 AST 63 5.2.4 感染 64 5.2.5 糖尿病 64 5.3氫離子幫浦阻斷劑 65 5.4 Hb & Hct 67 5.5 類固醇 67 5.6 EVL 68 5.7 MMF vs. MPS 68 第六章、結論 70 參考文獻 71 圖表 97 附錄 221 | |
dc.language.iso | zh-TW | |
dc.title | ABCB1、CYP3A4、CYP3A5、POR基因多型性及其他因素對腎臟與肝臟移植病人tacrolimus血中濃度之影響 | zh_TW |
dc.title | The influence of ABCB1、CYP3A4、CYP3A5、POR genetic polymorphism and other factors on tacrolimus blood concentration among renal and liver transplant patients | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 蔡孟昆(Meng-Kun Tsai),胡瑞恒(Rey-Heng Hu) | |
dc.contributor.oralexamcommittee | 沈麗娟(Li-Jiuan Shen) | |
dc.subject.keyword | tacrolimus,腎臟移植,肝臟移植,藥品動態學,藥品交互作用,臨床因素,基因多型性, | zh_TW |
dc.subject.keyword | tacrolimus,kidney transplantation,liver transplantation,pharmacokinetics,drug interactions,clinical factors,genetic polymorphism, | en |
dc.relation.page | 302 | |
dc.identifier.doi | 10.6342/NTU201602185 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2016-08-09 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 6.21 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。